Philip S Insel
Overview
Explore the profile of Philip S Insel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mackin R, Rhodes E, Kassel M, Kryza-Lacombe M, Burns E, Bickford D, et al.
Mol Psychiatry
. 2024 Nov;
PMID: 39511448
This study was conducted to clarify patterns of cortico-limbic volume abnormalities in late life depression (LLD) relative to non-depressed (ND) adults matched for amyloid β (Aβ) deposition and to evaluate...
2.
Kryza-Lacombe M, Kassel M, Insel P, Rhodes E, Bickford D, Burns E, et al.
J Int Neuropsychol Soc
. 2024 Sep;
30(9):807-811.
PMID: 39291416
Objective: Anxiety is a common comorbid feature of late-life depression (LLD) and is associated with poorer global cognitive functioning independent of depression severity. However, little is known about whether comorbid...
3.
Leuzy A, Raket L, Villemagne V, Klein G, Tonietto M, Olafson E, et al.
Alzheimers Dement
. 2024 Jul;
20(9):5833-5848.
PMID: 39041435
Introduction: Tau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer...
4.
A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings
Baumeister H, Vogel J, Insel P, Kleineidam L, Wolfsgruber S, Stark M, et al.
Brain
. 2024 Apr;
147(7):2400-2413.
PMID: 38654513
Memory clinic patients are a heterogeneous population representing various aetiologies of pathological ageing. It is not known whether divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer's...
5.
Young C, Smith V, Karjadi C, Grogan S, Ang T, Insel P, et al.
Alzheimers Dement
. 2024 Feb;
20(4):2552-2563.
PMID: 38348772
Introduction: Early cognitive decline may manifest in subtle differences in speech. Methods: We examined 238 cognitively unimpaired adults from the Framingham Heart Study (32-75 years) who completed amyloid and tau...
6.
Kryza-Lacombe M, Kassel M, Insel P, Rhodes E, Bickford D, Burns E, et al.
Int Psychogeriatr
. 2024 Jan;
36(11):1009-1020.
PMID: 38268483
Objectives: Late-life depression (LLD) is common and frequently co-occurs with neurodegenerative diseases of aging. Little is known about how heterogeneity within LLD relates to factors typically associated with neurodegeneration. Varying...
7.
Nutley S, Nguyen B, Mackin R, Insel P, Tosun D, Butters M, et al.
Am J Geriatr Psychiatry
. 2023 Dec;
32(4):497-508.
PMID: 38092621
Hoarding disorder (HD) is a debilitating neuropsychiatric condition that affects 2%-6% of the population and increases in incidence with age. Major depressive disorder (MDD) co-occurs with HD in approximately 50%...
8.
Kassel M, Kryza-Lacombe M, Insel P, Rhodes E, Satre D, Nelson J, et al.
Am J Geriatr Psychiatry
. 2023 Sep;
32(2):137-147.
PMID: 37770349
Objectives: Late life depression (LLD) and hoarding disorder (HD) are common in older adults and characterized by executive dysfunction and disability. We aimed to determine the frequency of co-occurring HD...
9.
Insel P, Kumar A, Hansson O, Mattsson-Carlgren N
Neurology
. 2023 Apr;
101(1):e20-e29.
PMID: 37085326
Background And Objectives: There is considerable heterogeneity in the association between increasing β-amyloid (Aβ) pathology and early cognitive dysfunction in preclinical Alzheimer disease (AD). At this stage, some individuals show...
10.
Donohue M, Langford O, Insel P, van Dyck C, Petersen R, Craft S, et al.
Pharm Stat
. 2023 Jan;
22(3):508-519.
PMID: 36627206
Mixed model repeated measures (MMRM) is the most common analysis approach used in clinical trials for Alzheimer's disease and other progressive diseases measured with continuous outcomes over time. The model...